Furthermore, miR-149-3p was shown to inhibit EMT by targeting TIMP metallopeptidase inhibitor 2 (TIMP2) and cyclin-dependent kinase inhibitor 1A (CDKN1A) mRNAs in ovarian cancer [95]. Here, CDKN1A is linked to ovarian cancer.